Overview
GHK-Cu is a copper tripeptide complex investigated in topical skin-care formulations, including products applied after carbon dioxide laser resurfacing.[1] The selected clinical evidence concerns particular topical preparations and treatment settings, which limits how broadly its findings can be applied.[1] A result following a skin procedure cannot establish the effectiveness or safety of an injectable product or a multi-peptide combination.[1] This guide therefore keeps the route and formulation attached to each finding while examining the reported skin outcomes, safety uncertainties, product-quality questions, and the evidence needed to support broader claims.
Benefits
The selected topical trial provides limited, procedure-specific evidence for GHK-Cu.[1] In a randomized study after carbon dioxide laser resurfacing, 13 patients completed follow-up.[1] Participants using the copper-peptide regimen reported greater improvement in overall skin quality, but objective assessments found no significant between-group improvement in wrinkles, overall skin quality, or resolution of redness.[1] This small, procedure-specific study does not establish that every copper-peptide serum reduces wrinkles or reverses skin aging.[1] Subjective satisfaction and objectively measured improvement should remain separate when judging a cosmetic claim, and findings from a topical regimen should not be transferred to injections.[1]
Safety
FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[2] The cited skin trial studied topical products after laser resurfacing and cannot establish injection safety.[1] Interpret these observations alongside the study population, route, and length of follow-up. A report of an event does not by itself establish causation, while a study that reports few events cannot exclude uncommon or delayed harms.
Contraindications
The cited topical trial reports cosmetic outcomes in 13 completers; its abstract does not establish safety during pregnancy, breastfeeding or in copper-handling disorders.[1] Eligibility criteria show whom researchers chose to study; they are not a complete assessment of who can safely receive a product. Any conclusion about suitability therefore needs the exact formulation, the person’s health history, and evidence that actually addresses the relevant circumstances.
Interactions
The cited trial compared topical skin-care regimens, not medication combinations; it does not establish compatibility with copper supplements, chelators or injectable peptide combinations.[1] To evaluate an interaction, the evidence needs to address the substances together and describe the outcome being monitored. Separate studies cannot establish the combined effect, and an unanswered interaction question should remain an uncertainty rather than becoming reassurance.
Forms & dosing
The cited randomized study examined topical GHK-Cu skin care after CO2 laser resurfacing; it provides no tested injection dose or injectable-combination protocol.[1] Clinical superiority of injected GHK-Cu over topical GHK-Cu has not been demonstrated in the human evidence reviewed here.[1][2] A topical study cannot establish the effectiveness or safety of systemic injection, because exposure and delivery are different.[1] FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[2] The argument that injection must work better because it bypasses the skin barrier is a mechanistic hypothesis, not a clinical result.[1][2] A useful comparison would require a controlled human study of defined formulations, relevant skin outcomes, and adverse events.[1][2]
Results & stopping
At 12 weeks, the 13-completer topical trial found no significant between-group objective improvement in wrinkles or overall skin quality, although patient-reported satisfaction favored GHK-Cu.[1] The abstract does not report a controlled withdrawal comparison establishing persistence after stopping.[1] Time to a measured response and persistence after treatment ends are separate questions. A meaningful interpretation needs to specify the outcome, when it was assessed, and whether follow-up actually continued after treatment stopped, rather than infer lasting benefit from an early response.
Product quality
FDA specifically identifies aggregation and peptide impurities as concerns for injectable GHK-Cu.[2] FDA also warns that contamination or incorrect strength in compounded medicines can cause serious harm.[3] A useful quality assessment needs to connect the tested sample to the actual product and explain what the test can establish. Evidence about identity or composition should remain distinct from evidence that the finished product is effective, suitable for a particular route, or clinically safe.
Status
FDA lists injectable GHK-Cu among withdrawn bulk-substance nominations.[2] U.S. cosmetic products generally do not undergo FDA preapproval, except certain color additives; therapeutic claims can cause a product marketed as a cosmetic to qualify as a drug.[4] Regulatory status needs to be read for the exact substance, finished product, indication, and jurisdiction being discussed. A research publication, a supplier listing, and a regulatory decision answer different questions, so none should be used as a substitute for the others.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
| Human researchSmall randomized post-procedure trial.[1] The selected topical trial provides limited, procedure-specific evidence for GHK-Cu.[1] In a randomized study after carbon dioxide laser resurfacing, 13 patients completed follow-up.[1] Participants using the copper-peptide regimen reported greater improvement in overall skin quality, but objective assessments found no significant between-group improvement in wrinkles, overall skin quality, or resolution of redness.[1] Main limitation: Small sample, mixed endpoints, procedure-specific context.[1] | ||
| Evidence type not classifiedNo direct comparative human study identified.[1][2] Clinical superiority of injected GHK-Cu over topical GHK-Cu has not been demonstrated in the human evidence reviewed here.[1][2] A topical study cannot establish the effectiveness or safety of systemic injection, because exposure and delivery are different.[1] FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[2] Main limitation: A delivery hypothesis does not establish benefit or safety.[1][2] |
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
A Torilis japonica Extract–GHK-Cu Complex Attenuates Th2 Cytokines and Promotes Keratinocyte Recovery: A Potential Antioxidant Strategy for Atopic Dermatitis
A gene expression signature of emphysemarelated lung destruction and its reversal by the tripeptide GHK
Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu
Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth
Enhanced biological properties of collagen/chitosan‑coated poly(ε‑caprolactone) scaffold by surface modification with GHK‑Cu peptide and 58S bioglass
Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms
Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway
Glycyl-L-histidyl-L-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway
Glycyl- l -histidyl- l -lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro
Human skin penetration of a copper tripeptide in vitro as a function of skin layer
Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy
Improved laccase production by Trametes versicolor using Copper-Glycyl-L-Histidyl-L-Lysine as a novel and high-efficient inducer
In Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer
In Vivo Stimulation of Connective Tissue Accumulation by the Tripeptide-Copper Complex Glycyl-L-histidyl-L-lysine-Cu2+ in Rat Experimental Wounds
Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application
Mass spectral and theoretical investigations of the transient proton-bound dimers on the cleavage processes of the peptide GHK and its analogues
Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs
The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline
The Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds
The copper(II)-binding tripeptide GHK, a valuable crystallization and phasing tag for macromolecular crystallography
The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6
The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function
The tri-peptide GHK-Cu complex ameliorates lipopolysaccharideinduced acute lung injury in mice
FAQs
Does topical GHK-Cu improve skin quality?
The selected topical trial provides limited, procedure-specific evidence for GHK-Cu.[1] In a randomized study after carbon dioxide laser resurfacing, 13 patients completed follow-up.[1] Participants using the copper-peptide regimen reported greater improvement in overall skin quality, but objective assessments found no significant between-group improvement in wrinkles, overall skin quality, or resolution of redness.[1] This small, procedure-specific study does not establish that every copper-peptide serum reduces wrinkles or reverses skin aging.[1] Subjective satisfaction and objectively measured improvement should remain separate when judging a cosmetic claim, and findings from a topical regimen should not be transferred to injections.[1]
Is injectable GHK-Cu better than a topical serum?
Clinical superiority of injected GHK-Cu over topical GHK-Cu has not been demonstrated in the human evidence reviewed here.[1][2] A topical study cannot establish the effectiveness or safety of systemic injection, because exposure and delivery are different.[1] FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[2] The argument that injection must work better because it bypasses the skin barrier is a mechanistic hypothesis, not a clinical result.[1][2] A useful comparison would require a controlled human study of defined formulations, relevant skin outcomes, and adverse events.[1][2]
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for GHK-Cu.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
7 sources
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006)Primary researchReview status · PendingSave study
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Accessed 2026-10-03)Regulatory assessmentSave study
- Understanding the Risks of Compounded Drugs (Accessed 2026-10-03)Regulatory guidanceSave study
- Cosmetics & U.S. Law (Accessed 2026-10-03)Regulatory guidanceSave study
- Does topical GHK-Cu actually work? Or is injecting better?
- GHK-CU topical vs injection
- GHK-Cu topical absorbtion
Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions
